Tff Pharmaceuticals Inc
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voricona… Read more
Tff Pharmaceuticals Inc (TFFP) - Net Assets
Latest net assets as of September 2024: $3.14 Million USD
Based on the latest financial reports, Tff Pharmaceuticals Inc (TFFP) has net assets worth $3.14 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.08 Million) and total liabilities ($3.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.14 Million |
| % of Total Assets | 44.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | -65.39% |
| 10-Year Change | N/A |
| Growth Volatility | 91.73 |
Tff Pharmaceuticals Inc - Net Assets Trend (2017–2023)
This chart illustrates how Tff Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tff Pharmaceuticals Inc (2017–2023)
The table below shows the annual net assets of Tff Pharmaceuticals Inc from 2017 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $9.57 Million | -58.19% |
| 2022-12-31 | $22.88 Million | -40.94% |
| 2021-12-31 | $38.74 Million | +3.74% |
| 2020-12-31 | $37.34 Million | +35.07% |
| 2019-12-31 | $27.64 Million | +199.04% |
| 2018-12-31 | $9.24 Million | +504437.64% |
| 2017-12-31 | $-1.83K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tff Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11832067600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.37K | 0.02% |
| Other Comprehensive Income | $-148.19K | -1.55% |
| Other Components | $128.04 Million | 1338.39% |
| Total Equity | $9.57 Million | 100.00% |
Tff Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Tff Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ALTCF
PINK:ALTCF
|
$181.83K |
|
Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund
NYSE:PTA
|
$181.93K |
|
FISH & PAYK HEALTH
BE:FPLB
|
$181.99K |
|
BBVA - Dusseldorf Stock Exchang
DU:BOY
|
$182.11K |
|
Grayscale Decentralized Finance (DeFi) Fund LLC
OTCQB:DEFG
|
$181.70K |
|
Qwest Corp. NT
NYSE:CTBB
|
$181.69K |
|
Electrica SA
LSE:ELSA
|
$181.62K |
|
EUROPLASMA EO 1-
F:1EZ0
|
$181.54K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tff Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 22,879,459 to 9,567,034, a change of -13,312,425 (-58.2%).
- Net loss of 21,243,231 reduced equity.
- Share repurchases of 2,875 reduced equity.
- New share issuances of 5,089,994 increased equity.
- Other comprehensive income decreased equity by 8,897.
- Other factors increased equity by 2,852,584.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.24 Million | -222.05% |
| Share Repurchases | $2.88K | -0.03% |
| Share Issuances | $5.09 Million | +53.2% |
| Other Comprehensive Income | $-8.90K | -0.09% |
| Other Changes | $2.85 Million | +29.82% |
| Total Change | $- | -58.19% |
Book Value vs Market Value Analysis
This analysis compares Tff Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.01 | $0.07 | x |
| 2017-12-31 | $0.00 | $0.07 | x |
| 2018-12-31 | $12.53 | $0.07 | x |
| 2019-12-31 | $100.09 | $0.07 | x |
| 2020-12-31 | $45.70 | $0.07 | x |
| 2021-12-31 | $39.02 | $0.07 | x |
| 2022-12-31 | $19.08 | $0.07 | x |
| 2023-12-31 | $5.34 | $0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tff Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -222.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2894.68%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.26x
- Recent ROE (-222.05%) is below the historical average (-71.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-369.27K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-178.42K |
| 2018 | -41.56% | 0.00% | 0.00x | 1.13x | $-4.77 Million |
| 2019 | -42.51% | 0.00% | 0.00x | 1.06x | $-14.52 Million |
| 2020 | -49.39% | 0.00% | 0.00x | 1.04x | $-22.17 Million |
| 2021 | -79.99% | -35149137.93% | 0.00x | 1.05x | $-34.86 Million |
| 2022 | -138.86% | 0.00% | 0.00x | 1.05x | $-34.06 Million |
| 2023 | -222.05% | -2894.68% | 0.06x | 1.26x | $-22.20 Million |
Industry Comparison
This section compares Tff Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tff Pharmaceuticals Inc (TFFP) | $3.14 Million | 0.00% | 1.26x | $181.70K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |